English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The introduction of 18 F-labeled prostate-specific membrane antigen (PSMA)-targeted PET/CT tracers, first 18 F-DCFPyL (2-(3-{1-carboxy-5-[(6- 18 F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) and more recently 18 F-PSMA-1007 (((3 S, 10 S, 14 S )-1-(4-((( S )-4-carboxy-2-(( S )-4-carboxy-2-(6- 18 F-fluoronicotinamido)butanamido)butanamido)methyl)phenyl)-3-(naphthalen-2-ylmethyl)-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid)), have demonstrated promising results for the diagnostic workup of prostate cancer. This clinical study presents an intraindividual comparison to evaluate tracer-specific characteristics of 18 F-DCFPyL versus 18 F-PSMA-1007. Methods: Twelve prostate cancer patients, drug-naïve or before surgery, received similar activities of about 250 MBq of 18 F-DCFPyL and 18 F-PSMA-1007 48 h apart and were imaged 2 h after injection on the same PET/CT scanner using the same reconstruction algorithm. Normal-organ biodistribution and tumor uptake were quantified using SUV max  Results: PSMA-positive lesions were detected in 12 of 12 prostate cancer patients. Both tracers, 18 F-DCFPyL and 18 F-PSMA-1007, detected the same lesions. No statistical significance could be observed when comparing the SUV max of 18 F-DCFPyL and 18 F-PSMA-1007 for local tumor, lymph node metastases, and bone metastases. With regard to normal organs, 18 F-DCFPyL had statistically significant higher uptake in kidneys, urinary bladder, and lacrimal gland. Vice versa, significantly higher uptake of 18 F-PSMA-1007 in muscle, submandibular and sublingual gland, spleen, pancreas, liver, and gallbladder was observed. Conclusion: Excellent imaging quality was achieved with both 18 F-DCFPyL and 18 F-PSMA-1007, resulting in identical clinical findings for the evaluated routine situations. Nonurinary excretion of 18 F-PSMA-1007 might present some advantage with regard to delineation of local recurrence or pelvic lymph node metastasis in selected patients; the lower hepatic background might favor 18 F-DCFPyL in late stages, when rare cases of liver metastases can occur.

the journal of nuclear medicine

Intraindividual Comparison of <sup>18</sup>F-PSMA-1007 and <sup>18</sup>F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study

Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study

Intraindividual Comparison of ¹⁸F-PSMA-1007 and ¹⁸F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study